Dr. Talat Kheshgi, M.D.
What this data tells you about Dr. Kheshgi
Dr. Talat Kheshgi is a rheumatology specialist in Dallas, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Kheshgi performed 50,695 Medicare services across 3,795 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kheshgi received a total of $6,942 from 26 pharmaceutical and/or device companies across 217 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kheshgi is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) | 40,400 | $4 | $15 |
| Denosumab injection (Prolia/Xgeva) | 4,080 | $18 | $69 |
| Comprehensive metabolic blood panel | 662 | $10 | $32 |
| Complete blood count (CBC) with differential | 648 | $8 | $23 |
| Blood draw (venipuncture) | 644 | $8 | $27 |
| Sed rate test (inflammation marker) | 630 | $3 | $8 |
| C-reactive protein test (inflammation marker) | 629 | $5 | $16 |
| Office visit, established patient (30-39 min) | 538 | $89 | $377 |
| Vitamin D level test | 277 | $29 | $89 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 270 | $56 | $218 |
| Measurement of antibody for assessment of autoimmune disorder, any method | 251 | $18 | $54 |
| Measurement of complement (immune system proteins), antigen, | 240 | $12 | $36 |
| Screening test for antibody to noninfectious agent | 121 | $12 | $36 |
| Screening test for autoimmune disorder | 120 | $12 | $36 |
| Office visit, established patient (20-29 min) | 111 | $60 | $266 |
| Measurement of antibody for rheumatoid arthritis assessment | 98 | $13 | $39 |
| Rheumatoid factor level | 89 | $6 | $17 |
| Hepatitis c antibody measurement | 89 | $14 | $43 |
| Uric acid level test | 87 | $4 | $14 |
| Hepatitis b core antibody measurement | 83 | $12 | $36 |
| Hepatitis b surface antibody measurement | 83 | $11 | $32 |
| Detection test by immunoassay technique for hepatitis b surface antigen | 83 | $10 | $31 |
| New patient office visit, complex (60-74 min) | 78 | $161 | $648 |
| Creatine kinase (cardiac enzyme) level, total | 70 | $6 | $20 |
| Joint injection, major joint | 67 | $63 | $191 |
| Urinalysis with microscopic exam | 65 | $3 | $9 |
| Automated urinalysis | 50 | $2 | $7 |
| Office visit, established patient, complex (40-54 min) | 31 | $135 | $530 |
| Thyroid stimulating hormone (TSH) test | 26 | $16 | $50 |
| Injection, methylprednisolone acetate, 80 mg | 25 | $8 | $37 |
| Flu vaccine, high-dose | 18 | $71 | $587 |
| Flu vaccine administration | 18 | $31 | $80 |
| New patient office visit (45-59 min) | 14 | $112 | $491 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (71%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Kheshgi is a mixed practice specialist, with above-average Medicare volume (top 22% in TX), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Kheshgi experienced with certolizumab injection (cimzia)?
Does Dr. Kheshgi receive payments from pharmaceutical companies?
How do Dr. Kheshgi's costs compare to other rheumatologists in Dallas?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology